Business context and reporting period
This filing is a Form 10-Q for the quarter ended June 30, 2018, covering the three and nine months ended that date. The filing identifies the registrant as Stellar Biotechnologies, Inc., not Edesa Biotech, Inc.; verify that this is the intended filing. Stellar develops, manufactures, and sells keyhole limpet hemocyanin (KLH) for research and immunotherapy applications. All amounts below are U.S. dollars.
Key financial metrics
| Metric | Three months ended June 30, 2018 | Nine months ended June 30, 2018 | Comparable 2017 period |
|---|---|---|---|
| Revenue | $73,053 | $157,592 | $20,532 and $225,407, respectively |
| Operating loss | $1,158,401 | $3,892,137 | $1,293,616 and $3,855,649, respectively |
| Net loss | $1,156,672 | $3,909,945 | $1,220,361 and $3,809,710, respectively |
| Basic and diluted loss per share | $0.38 | $1.93 | $0.84 and $2.63, respectively |
| Operating cash used | Not separately provided | $3,644,272 | $3,582,534 used in the nine months ended June 30, 2017 |
At June 30, 2018, cash and cash equivalents were $5.82 million and short-term Treasury investments were $5.46 million, for total cash and investments of $11.28 million. Working capital was $11.22 million; total assets were $12.80 million and shareholders’ equity was $12.39 million. Current liabilities were $414,610, consisting of accounts payable and accrued liabilities; the balance sheet reports no debt. Nine-month capital expenditures were $361,400. No gross-margin or quarterly cash-flow figure is separately reported.
Material changes versus prior comparable periods
- Third-quarter revenue increased to $73,053 from $20,532, while net loss narrowed to $1.16 million from $1.22 million.
- Nine-month revenue declined to $157,592 from $225,407, principally because of lower product sales and no contract-services revenue in 2018. Nine-month net loss widened to $3.91 million from $3.81 million.
- Nine-month research and development expense rose to $1.59 million from $1.33 million, mainly reflecting manufacturing scalability and throughput work, engineering lots, and contracted research. General and administrative expense fell to $2.10 million from $2.31 million.
- Cash and investments increased from $6.57 million at September 30, 2017 to $11.28 million at June 30, 2018, largely reflecting equity and warrant financing. The company completed a public offering and warrant exercises; the resulting share issuance increased potential dilution. A one-for-seven reverse split took effect May 4, 2018.
Outlook, risks, contingencies, and unusual items
- Management planned to fund operations for the next 12 months using available cash and investments and product sales, while retaining flexibility to adjust spending. It anticipated further losses and said it may seek additional debt or equity financing.
- Product sales depend on the timing and progress of customers’ clinical studies, making sales volumes variable. Two customers accounted for 60% of nine-month revenue; customer and geographic concentrations remain relevant.
- The company is investing in manufacturing scale-up and aquaculture infrastructure. Nine-month capital spending increased from $200,365 in 2017; further investment depends on clinical milestones and market conditions.
- The Neostell joint venture’s milestone deadline was extended to December 31, 2018. Following Neovacs’ July 3, 2018 announcement of Phase 2b lupus-study results, the parties were discussing milestones and potential advancement. Failure to meet milestones could lead to dissolution unless the parties agree otherwise or one buys out the other’s interest.
- Commitments included approximately $404,000 of future minimum lease payments and approximately $193,000 of purchase obligations expected to be fulfilled within 12 months. The filing reports no material legal proceedings, no material changes to previously disclosed risk factors, and no material off-balance-sheet arrangements.
- Management reported disclosure controls were effective as of June 30, 2018 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Stellar Biotechnologies, Inc., despite the request metadata naming Edesa Biotech, Inc.
- Assess cash runway against recurring operating cash use, planned manufacturing investment, and management’s stated 12-month funding plan.
- Review the terms, exercise prices, expiry dates, and potential dilution from the 2018 offerings and outstanding warrants.
- Track customer clinical-program progress, revenue concentration, and the Neostell milestone discussions before assuming growth in KLH sales.
- Interpret per-share comparisons in light of the May 2018 reverse split and the substantial increase in shares issued during the period.